MELISSA VELASCO: Open Payments
NPI 1326736414 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,931 in 104 payments from 16 companies in 2025. Trend: 2023 $458 · 2024 $1,675 · 2025 $2,931
Food & beverage: $2,931
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 18 | $693 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $594 |
| ABBVIE INC. | 16 | $525 |
| Corium, LLC | 8 | $230 |
| Alkermes, Inc. | 14 | $228 |
| Lundbeck LLC | 5 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $114 |
| Otsuka America Pharmaceutical, Inc. | 4 | $113 |
| Collegium Pharmaceutical, Inc. | 3 | $62 |
| Noven Therapeutics, LLC | 3 | $58 |
Products named: CAPLYTA, VRAYLAR, HETLIOZ, FANAPT, REXULTI, Azstarys, ARISTADA, TRINTELLIX.
Industry payments across KY — which companies pay providers there.
